Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Oxaliplatin

Leucovorin

Fluorouracil

Irinotecan

Levoleucovorin

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Topoisomerase I Inhibitors

Enzyme Inhibitors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folinic Acid

Folate

Vitamin B9

mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）

100 mg/m2, IV (in the vein) on day 1,15 of each cycle.

Campto, Topotesin

S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)

TS-1

L-Plat

Isovorin

400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.

5-FU

Yoshito Komatsu, MD, PhD

This randomized phase III study compares safety and efficacy of two sequence arms in advanced colorectal cancer: irinotecan and S-1 (IRIS) followed by oxaliplatin containing regimen (arm A), or l-leucovorin (l-LV), 5-FU and oxaliplatin (mFOLFOX6) followed by irinotecan containing regimen (arm B).

A multicenter randomized open-label controlled phase III study is conducted in patients with inoperable advanced or metastatic colorectal cancer who receive no previous chemotherapy. Usefulness of IRIS and mFOLFOX6 regimens as the 1st-line therapy for colorectal cancer is evaluated in PFS, MST, incidence and severity of adverse events

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Irinotecan Combined With S-1( IRIS ) Followed by mFOLFOX6 Regimen Versus mFOLFOX6 Followed by IRIS Regimen in Advanced Colorectal Cancer

Hokkaido University Hospital

Hokkaido Gastrointestinal Cancer Study Group

Colonic Neoplasms

Herbal and Botanical

Cola

Medical Monitor

The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.

Study Evaluating Isovorin in Colon Cancer

Post-Approved Phase III Study of 1-LV/5FU Therapy

Wyeth is now a wholly owned subsidiary of Pfizer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer	NCT00316745	Metastatic Colo...	Campto, Topotes... TS-1 L-Plat Isovorin 5-FU	18 Years - 75 Years	Hokkaido Gastrointestinal Cancer Study Group
Study Evaluating Isovorin in Colon Cancer	NCT00195585	Colon Cancer	Isovorin UFT	20 Years - 75 Years	Wyeth is now a wholly owned subsidiary of Pfizer

Spots Global Cancer Trial Database for isovorin

Every month we try and update this database with for isovorin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for isovorin

Every month we try and update this database with for isovorin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for isovorin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.